Is Maintenance Bacillus Calmette-Guérin Really Necessary?

European Urology

Volumn 54, Issue 5, 2008, Pages 971-973

  Herr, Harry W ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

BLADDER CANCER; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; EDITORIAL; HUMAN; MAINTENANCE THERAPY; PRIORITY JOURNAL; TRANSURETHRAL RESECTION;

ADJUVANTS, IMMUNOLOGIC; BCG VACCINE; CLINICAL TRIALS AS TOPIC; CYSTECTOMY; FOLLOW-UP STUDIES; HUMANS; POSTOPERATIVE CARE; PROGNOSIS; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 55649120015     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.06.062     Document Type: Editorial

References (19)

1. Babjuk M., Oosterlinck W., Sylvester R., et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54 (2008) 303-314
2. Lamm D.L., Blumenstein B.A., Crissman J.D., et al. Maintenance BCG immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163 (2000) 1124-1129
3. Sylvester R.J., van der Meijden, and Lamm D.L. Intravesical BCG reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168 (2002) 1964-1970
4. Bohle A., and Bock P.R. Intravesical BCG versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63 (2004) 682-687
5. Badalament R.A., Herr H.W., Wong G.Y., et al. A prospective randomized trial of maintenance versus nonmaintenance intravesical BCG therapy of superficial bladder cancer. J Clin Oncol 5 (1987) 441-449
6. Palou J., Laguna P., Millan-Rodriquez F., et al. Control group and maintenance treatment with BCG for carcinoma in situ and/or high grade bladder tumors. J Urol 165 (2001) 1488-1491
7. Hudson M.A., Ratliff T.L., Gillen D.P., et al. Single course versus maintenance BCG therapy for superficial bladder tumors: a prospective randomized trial. J Urol 138 (1987) 295-298
8. Tachibana M., Jitsukawa S., Iigaya T., et al. Comparative study on prophylactic intravesical instillation of BCG and adriamycin for superficial bladder cancers. Nippon Hinyokika Gakkai Zasshi 80 (1989) 1459-1465
9. Akaza H., Hinotsu S., Aso Y., et al. BCG treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Cancer 75 (1995) 552-559
10. Simmonds M., Higgins J.P., Stewart L.A., et al. Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. Clinical Trials 2 (2005) 209-217
11. Cook D. Cumulative meta analysis of clinical trials builds evidence for exemplary medical care: discussion. J Clin Epidemiol 48 (1995) 59-60
12. Cookson M.S., Herr H.W., Zhang Z.-F., et al. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 158 (1997) 62-67
13. Witjes J.A., Caris C.T.M., Mungan N.A., et al. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and BCG versus mitomycin C alone in patients with superficial bladder cancer. J Urol 160 (1998) 1668-1673
14. Vegt P.D.J., Witjes J.A., Witjes W.P.J., et al. A randomized study of intravesical mitomycin C Tice and BCG RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. J Urol 153 (1995) 929-935
15. Witjes J.A., van der Meijden A.P., Collettee L., et al. Long-term follow-up of an EORTC randomized prospective trial comparing intravesical BCG-RIVM and mitomycin C in superficial bladder cancer. Urology 52 (1998) 403-409
16. Herr H.W., Laudone V.P., Badalament R.A., et al. BCG therapy alters the progression of superficial bladder cancer. J Clin Oncol 6 (1988) 1450-1455
17. Joudi F.N., Smith B.J., O'Donnell M.A., et al. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol 175 (2006) 1634-1637
18. Andius P., and Holmang S. BCG therapy in stage Ta/T1 bladder cancer: progression factors for time to recurrence and progression. BJU Int 93 (2004) 980-984
19. Herr H.W. Age and outcome of superficial bladder cancer treated with BCG therapy. Urology 70 (2007) 65-68